Last Updated: May 12, 2026

Claims for Patent: 10,172,850

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,172,850

Title:	Substituted diketopiperazine analogs for use as drug delivery agents
Abstract:	Disclosed are drug delivery systems for the delivery of small molecule and macromolecular drugs. More particularly, disclosed are substituted analogs of 3,6-di(alkyl-4 aminobutyl)-2,5-diketopiperazine (which may also be referred to DKP), their use in the formulation of both small molecule and macromolecular drugs including therapeutic, prophylactic and diagnostic agents, stabilizing agents and systems for their delivery.
Inventor(s):	Kraft; Kelly Sullivan (Poughquag, NY)
Assignee:	MannKind Corporation (Westlake Village, CA)
Application Number:	15/488,915
Patent Claims:	1. A dry powder composition comprising an active agent and a diketopiperazine of the formula: ##STR00005## wherein R is H or an alkyl group of 1-10 carbons; n or m=0-20; X is an amide, ester, sulfone, sulfoxide, amine, or ketone; and Y is an amide, acid, hydroxyl, phenol, phosphonic acid, or thiol. 2. The dry powder composition of claim 1 wherein R is hydrogen, n=3, m is C.dbd.C, X is --NHC(O)--, and Y is COOH. 3. The dry powder composition of claim 1 wherein R is hydrogen, n=2, m is C.dbd.C, X is --NHC(O)--, and Y is COOH. 4. The dry powder composition of claim 1 wherein R is an isopropyl, n=3, m is C.dbd.C, X is --NHC(O)--, and Y is COOH. 5. The dry powder composition of claim 1 wherein the active agent is a peptide, protein, polypeptide, small molecule, or nucleic acid molecule. 6. The dry powder composition of claim 5, wherein the active agent is selected from the group consisting of insulin, glucagon, glucagon like peptide 1 (GLP-1), calcitonin, parathyroid hormone 1-34, bioactive fragment of parathyroid hormone, octreotide, leuprolide, and RSV peptide, granulocyte colony stimulating factor (GM-CSF), peptide YY, oxyntomodulin, felbamate, cannabinoid antagonists, cannabinoid agonists, muscurinic antagonists, muscarinic agonists, heparin, low molecular weight heparin, cromolyn, sildenafil, vardenafil, tadalafil, growth hormone, AZT, DDI, lamotrigine, chorionic gonadotropin releasing factor, luteinizing release hormone, beta-galactosidase, exendins 1-4, ghrelin, tryptin, and analogs and fragments thereof. 7. The dry powder composition of claim 6, wherein the active agent is insulin or an insulin analog. 8. The dry powder of claim 6, wherein the active agent is parathyroid hormone 1-34 or a bioactive fragment thereof. 9. The dry powder of claim 6, wherein the active agent is leuprolide. 10. The dry powder of claim 6, wherein the active agent is GLP-1 or an analog thereof. 11. The dry powder of claim 6, wherein the active agent is granulocyte macrophage colony stimulating factor. 12. The dry powder of claim 6, wherein the active agent is a cannabinoid agonist. 13. The dry powder of claim 6, wherein the active agent is a cannabinoid antagonist. 14. The dry powder of claim 6, wherein the active agent is sildenafil. 15. A method of increasing plasma level of an active agent in a patient in need thereof, comprising administering to the patient by inhalation the dry powder composition of claim 1. 16. A dry powder composition comprising a cannabinoid and a diketopiperazine of the formula: ##STR00006## wherein R is H or an alkyl group of 1-10 carbons; n or m=0-20; X is an amide, ester, sulfone, sulfoxide, amine, or ketone; and Y is an amide, acid, hydroxyl, phenol, phosphonic acid, or thiol.

Details for Patent 10,172,850

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	January 15, 1974	⤷ Start Trial	2037-04-17
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	December 27, 1984	⤷ Start Trial	2037-04-17
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 15, 1985	⤷ Start Trial	2037-04-17
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 16, 1990	⤷ Start Trial	2037-04-17
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	March 26, 1974	⤷ Start Trial	2037-04-17
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.